Table 3. Univariate analysis for risk factors associated with IFIs among AML patients with induction chemotherapy.
| With proven or probable IFIs | p value | With all-category IFIs | p value | |
|---|---|---|---|---|
| n (%) | n (%) | |||
| All patients (N = 298) | 32 (10.7%) | 103 (34.6%) | ||
| Age | NS | 0.046 | ||
| ≧60 years (n = 91) | 12 (13.2%) | 35 (38.5%) | ||
| 40–59 years (n = 121) | 11 (9.1%) | 32 (26.4%) | ||
| 16–39 years (n = 86) | 9 (10.5%) | 36 (41.9%) | ||
| Sex | NS | NS | ||
| Male (n = 158) | 19 (12.0%) | 60 (38.0%) | ||
| Female (n = 140) | 13 (9.3%) | 43 (30.7%) | ||
| Antecedent hematologic disease | NS | 0.038 | ||
| Yes (n = 57) | 8 (14.0%) | 26 (45.6%) | ||
| No (n = 241) | 24 (10.0%) | 77 (32.0%) | ||
| Chemotherapy | 0.013 | NS | ||
| Standard (n = 246) | 31 (12.6%) | 87 (35.4%) | ||
| Low-intensity (n = 52) | 1 (1.9%) | 16 (30.7%) | ||
| Response to chemotherapy | 0.046 | 0.039 | ||
| CR (n = 161) | 13 (8.1%) | 43 (26.7%) | ||
| PR (n = 38) | 3 (7.9%) | 10 (26.3%) | ||
| RD (n = 76) | 11 (14.5%) | 37 (48.7%) | ||
| Undefined (n = 23) |
AML, acute myeloid leukemia; CR, complete remission; IFI, invasive fungal infection; PR, partial remission; RD, resistant disease